Fragmenting the platelet to reduce metastasis.
In this issue of Blood, Zhang et al describe an antiplatelet reagent attacking metastasis, the most deadly aspect of cancer.(1) Their experiments outline an early-stage preclinical approach providing proof-of-principle for antiplatelet strategies that may ultimately lead to an improved prognosis for the cancer patient.(1)